# PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2011

- Company: [PharmaCyte Biotech, Inc.](/companies/pmcb.md) (CIK 1157075)
- Form: 10-Q
- Filed: 2011-12-15
- Accepted by EDGAR: Dec 15, 2011, 15:00 ET
- Period: 2011-10-31
- Accession: 0001262463-11-000325
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1157075/000126246311000325/nuvilex10q10312011.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1157075/000126246311000325/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2011-10-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2011-08-01 to 2011-10-31 | $19.8k | us-gaap:Revenues |
| Revenue | 6 months, 2011-05-01 to 2011-10-31 | $39.6k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2011-08-01 to 2011-10-31 | $6.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2011-05-01 to 2011-10-31 | $21.7k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2011-08-01 to 2011-10-31 | $13.8k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2011-05-01 to 2011-10-31 | $17.9k | us-gaap:GrossProfit |
| Interest expense | 3 months, 2011-08-01 to 2011-10-31 | −$33.4k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2011-05-01 to 2011-10-31 | −$66.8k | us-gaap:InterestExpense |
| Net income | 3 months, 2011-08-01 to 2011-10-31 | −$437.2k | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2011-05-01 to 2011-10-31 | −$1.1m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2011-08-01 to 2011-10-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2011-05-01 to 2011-10-31 | $0.00 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months, 2011-05-01 to 2011-10-31 | −$171.2k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2011-10-31 | $14.5k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2011-10-31 | $606.5k | us-gaap:AssetsCurrent |
| Total assets | at 2011-10-31 | $1.7m | us-gaap:Assets |
| Current liabilities | at 2011-10-31 | $3.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2011-10-31 | $3.5m | us-gaap:Liabilities |
| Short-term borrowings | at 2011-10-31 | $2.4m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2011-10-31 | −$2.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 6,205 characters.

*The following discussion may contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed here. Factors that could cause or contribute to such differences include, but are not limited to, any factors discussed in this section as well as factors described in “Part II, Item 1A – Risk Factors.”*

### RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED OCTOBER 31, 2011 AND 2010

### SALES

Revenues from operations for the three months ending October 31, 2011 compared to 2010 rose slightly from $13,015 to $13,808, presumably from ending sales in the prior year. On the other hand, revenue from operations dropped for the six months ending October 31, 2011 compared to a year earlier, from $33,048 to $17,895, respectively, potentially associated with the overall slow-down observed in the economy, the inherent challenges in restarting a product, initializing pricing increases for the first time in 6 years according to actual costs for the products, and greater operations in the spring of 2010 (prior to ending sales in 2010). There was a decrease in quarterly revenue on a yearly basis (October 31, 2011 and 2010) of $39,606 and $42,814, respectively, primarily attributable to costs and efforts of reinitiating sales of Cinnergen™.

Compared to July 2011, the revenue from sales has increased more than 3 fold from $4,087 for the three months ending on July 31, 2011 to $13,808 for the three months ending on October 31, 2011. In addition, the total operating expenses for the company have decreased by more than 30% from $656,687 to $417,539 for the three months ending on July 31, 2011 compared to October 31, 2011, respectively, most likely from careful planning and operating of the company by its principals and critical aid by related parties.

### SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

A summary of the Company’s selling, general and administrative costs are as follows:

During the six months ended October 31, 2011 and October 31, 2010, the Company incurred increased sales and marketing expenses from $128,730 to $7,000 primarily associated with the restarting of the Cinnergen™ and Cinnechol™ products, creation of a secure internet sales web marketing website, and payment of prior year debts. The overall general and administrative expenses all increased during the six months ended October 31, 2011 and October 31, 2010, respectively, from $131,561 to $1,074,224 primarily as a result of the payment of officers with Nuvilex stock, restart of the company, and legal and professional fees associated with ongoing operations and prior year debt.

During the three months ended October 31, 2011 and October 31, 2010, the scenario is similar, with an increase in the overall net operating loss from operations to $403,731 from $19,178, primarily due to the same reasons: payments to officers in stock, company restart, and legal and professional fees. Nonetheless, it is important to note that the overall net operating loss from operations decreased to ~60% of its former value from $652,600 to $403,731 in the three month periods ending July 31, 2011 compared to October 31, 2011 due to a decrease in general and administrative expenses as well as legal and professional fees.

However, the Company only paid $3,000 in sales and marketing expenses in the three months from July 31, 2011 to October 31, 2011, dropping from $125,130 in the first three months ending July 31, 2011 which were due to costs of increasing investor exposure and awareness including stock costs.

Legal and professional fee expenses decreased dramatically to only $8,161 in the 3 months ending October 31, 2011 from the high of $59,954 ending July 31, 2011, as a result of addressing prior issues, and efficient use of funds, prepaid expenses and continued support from numerous individuals and companies. This is an increase from $0 to the $8,161 for the three months ending October 31, 2010 compared to 2011. The costs increased to $68,115 during the six months ended October 31, 2011 from $25,151 during the six months ended October 31, 2010 primarily due to expanding versus ending operations of the Company during those periods.

It is important to note there has also been a dramatic decrease by ~50% in general and administrative expenses for the three months ended October 31, 2011 of $83,013 as compared to the prior three months ended July 31, 2011 of $166,039. The decrease is primarily attributable to a decrease in unnecessary operating expenses, consolidation, as well as the efforts provided by the Consumer Healthcare Distribution Center in Mesa, AZ and the Sales and Marketing Division in Payson, AZ. Nonetheless, this is an increase when compared to the prior 3 or 6 month period of 2010 as a result of the operational needs of the Company.

### LIQUIDITY AND CAPITAL RESOURCES

As of October 31, 2011, the Company had a working capital deficit of $2,914,546, which is lower than the prior 3 months ending July 31, 2011 of $2,953,016. This is primarily through decreased spending, careful planning and the generous support of interested investors, for which the Company is extremely grateful.

By adjusting the Company’s operations and through bridge financing being provided by existing interested investors and shareholders, management believes it has sufficient capital resources to meet projected cash flow needs. Failure by the Company to generate sufficient liquidity from operations or in raising sufficient capital resources on acceptable terms would have a materially adverse effect on the Company’s business, results of operations, liquidity and financial condition.

The Company’s independent certified public accountants have stated in their reports, included as part of the Company’s audited financial statements for the fiscal years ended April 30, 2011 and 2010, respectively, that the Company has recurring losses from operations which raise doubt about the Company’s ability to continue as a going concern. It is the aim and effort of the managements of Nuvilex and ASPL to prevent this.

We have no off-balance sheet arrangements, special purpose entities, financing partnerships or guarantees.

## Controls and procedures

As filed, 3,546 characters.

### Evaluation of and Report on Internal Control over Financial Reporting

The management of Nuvilex, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of July 31, 2011. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework.

Based on its assessment, management concluded that, as of October 31, 2011, the Company’s internal control over financial reporting is ineffective based on those criteria as they relate to timely and accurate filing. Nonetheless, effort has been made to change this.

### Changes in Internal Control

During the three months ended October 31, 2011 there were no substantial changes in our internal control over financial reporting (as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Exchange Act) that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, even though effort has been made to advance this area.

## Risk factors

As filed, 18,913 characters.

*You should carefully consider these factors that may affect future results, together with all of the other information included in this Form 10-K, in evaluating the business and the Company. The risks and uncertainties described below are those that the Company currently believes may materially affect its business and results of operations. Additional risks and uncertainties that Nuvilex is unaware of or that it currently deems immaterial also may become important factors that affect its business and result of operations. Nuvilex’ common shares involve a high degree of risk and should be purchased only by investors who can afford a loss of their entire investment. Prospective investors should carefully consider the following risk factors concerning the Company’s business before making an investment.*

*In addition, you should carefully consider these risks when you read “forward-looking” statements elsewhere in this Form 10-K. These are statements that relate to the Company’s expectations for future events and time periods. Generally, the words “anticipate,” “expect,” “intend,” and similar expressions identify forward-looking statements. Forward-looking statements involve risks and uncertainties, and future events and circumstances could differ significantly from those anticipated in the forward-looking statements.*

### Doubt Regarding Ability to Continue as a Going Concern

Nuvilex’s financial statements have been presented on the basis that it is and will remain a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company had minimal revenues and incurred net operating losses for the period October 1999 (inception) to October 31, 2011. As the Company’s independent auditors have concluded, these factors create an uncertainty about Nuvilex’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent, among other factors, on its success in marketing its products, containing costs, establishing a credit facility, and/or raising additional equity capital. The financial statements of Nuvilex do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

### Early Revenue Stage Company: Generation of Revenues

Nuvilex is an early revenue stage company and an investor cannot reasonably determine if the Company will ever be profitable. Nuvilex is likely to continue to experience financial difficulties during its early revenue stage and beyond. The Company may be unable to operate profitably, even if it generates additional revenues. Nuvilex may not obtain the necessary working capital to continue developing and marketing its products. Furthermore, Nuvilex’s products may not receive sufficient interest to generate revenues or achieve profitability.

### Need for Future Capital: Long-Term Viability of Company

Nuvilex will need additional capital to continue its operations.

There can be no assurance that the Company will generate revenues from present operations or obtain sufficient capital on acceptable terms, if at all. Failure to obtain such capital or generate such operating revenues would have an adverse impact on the Company’s financial position, operations and ability to continue as a going concern. Nuvilex’ operating and capital requirements during the next fiscal year and thereafter will vary based on a number of factors, including the level of sales and marketing activities for its services and products. There can be no assurance that additional private or public financing, including debt or equity financing, will be available as needed or if available, on terms favorable to the Company. Additionally, any future equity financing may be dilutive to stockholders present ownership levels and such additional equity securities may have rights, preferences, or privileges that are senior to those of Nuvilex’ existing common stock.

Furthermore, debt financing, if available, will require payment of interest and may involve restrictive covenants that could impose limitations on the flexibility of the Company to operate. Nuvilex’s failure to successfully obtain additional funding may jeopardize its ability to continue the business and its operations.

### Unpredictability of Future Revenues: Potential Fluctuations in Operating Results

The Company is currently unable to accurately forecast its revenues. Typically, current and future expense levels are based largely on marketing and development plans and estimates of future revenues. Sales and operating results will generally depend on the volume and timing of orders and on the Company’s ability to fulfill such orders, both of which are difficult to forecast at this stage. Nuvilex may be unable to adjust spending in a timely manner to compensate for any unexpected revenue shortfall. Accordingly, any significant shortfall in revenues in relation to planned expenditures could have an immediate adverse effect on the Company’s business, prospects, financial condition and results of operations. Further, as a strategic response to changes in the competitive environment, Nuvilex may from time to time make certain pricing, service or marketing decisions that could have a materially adverse effect on its business, prospects, financial condition and results of operations.

Nuvilex may experience significant fluctuations in future operating results due to a variety of factors, many of which are outside the Company’s control. Factors that may affect operating results include: (i) the ability to obtain and retain customers, attract new customers at a steady rate and maintain customer satisfaction with products, (ii) the announcement or introduction of new services by Nuvilex or its competitors, (iii) price competition, (iv) the level of use and consumer acceptance of its products, (v) the amount and timing of operating costs and capital expenditures relating to expansion of the business, operations and infrastructure, (vi) governmental regulations, and (vii) general economic conditions.

### Flaws and Defects in Products

Products offered by Nuvilex may contain undetected flaws or defects when first introduced or as new versions are released. Any inaccuracy or defects may result in adverse product reviews and a loss or delay in market acceptance. There can be no assurance that flaws or defects will not be found in Nuvilex products. Flaws and defects, if found, could have a materially adverse effect upon the business operations and financial condition of the Company. Marketing of any of the Company’s potential products may expose the Company to liability claims resulting from the use of the Company’s products. These claims might be made by consumers, health care providers, sellers of the Company’s products or others. A claim, particularly resulting from a clinical trial, or a product recall could harm the Company’s business, results of operations, financial condition, cash flow and future prospects.

### Stock Price Volatility

The market price of the Company’s stock has fluctuated significantly in the past and may continue to fluctuate in the future. The Company believes that such fluctuations will continue as a result of many factors, including financing plans, future announcements concerning the Company, the Company’s competitors or principal customers regarding financial results or expectations, industry supply or demand dynamics, new product introductions, governmental regulations, the commencement or results of litigation or changes in earnings estimates by analysts. In addition, in recent years the stock market has experienced significant price and volume fluctuations often for reasons outside the control of the particular companies. These fluctuations as well as general economic, political and market conditions may have an adverse affect on the market price of the Company’s common stock.

### Worldwide Economic Conditions

The Company’s financial performance is significantly affected by worldwide economic conditions and the related impact on levels of consumer spending, which has recently deteriorated significantly in many countries and regions, including the U.S., and may remain depressed for the foreseeable future. Demand for the Company’s products is adversely affected by negative macroeconomic factors affecting consumer spending. The severe tightening of consumer credit, low level of consumer liquidity, and extreme volatility in credit and equity markets have weakened consumer confidence and decreased consumer spending. These and other economic factors have reduced demand for the Company’s products and harmed the Company’s business, financial condition and results of operations, and to the extent such economic conditions continue, they could cause further harm to the Company’s business, financial condition and results of operations.

### Dependence on Sales through Retailers and Distributors

The Company’s business depends significantly upon sales through retailers and distributors, and if the Company’s retailers and distributors are not successful, the Company could experience reduced sales, substantial product returns or increased price protection, any of which would negatively impact the Company’s business, financial condition and results of operations. A significant portion of the Company’s sales are made through retailers, either directly or through distributors. If the Company’s retailers and distributors are not successful due to weak consumer retail demand caused by the current worldwide economic downturn, decline in consumer confidence, or other factors, the Company could continue to experience reduced sales as well as substantial product returns or price protection claims, which would harm the Company’s business, financial condition and results of operations.

### Limited Senior Management Personnel: Management of Potential Growth; New Management Team

Under Nuvilex’s business plan, significant and material matters of business must be conducted and concluded in a timely fashion. The execution of the Company’s business plan is expected to place a significant strain on the Company’s management while providing little or no immediate compensation.

There can be no assurance that Nuvilex’s planned personnel, systems, procedures and controls will be adequate to support its future operations, that management will be able to hire, train, retain, motivate and manage personnel or that its management will be able to successfully identify, manage and exploit existing and potential market opportunities. If Nuvilex is unable to manage growth effectively, the Company’s business, prospects, financial condition, results and operations could be adversely affected.

### Competition

The market in which Nuvilex competes is highly competitive, and the Company has no assurance that it will be able to compete effectively, especially against established industry competitors with significantly greater financial resources. The Company expects to face competition from a few competitors with significantly greater financial resources, well-established brand names and large, existing customer bases. Nuvilex expects the level of competition to intensify in the future.

### Dependence on Management

Nuvilex’s performance will be substantially dependent on the continued services and on the performance of the current senior management and other key personnel of the Company. Nuvilex’s performance will also depend on the Company’s ability to retain and motivate its other officers and key employees. The loss of Nuvilex’s chief executive officer or other key employees could have a materially adverse effect on the Company’s business, prospects, financial condition and results of operations. Nuvilex’s future success will depend on its ability to identify, attract, hire, train, retain and motivate other highly skilled technical, managerial, merchandising, and marketing and customer service personnel. Competition for such personnel is intense and there can be no assurance that Nuvilex will be able to successfully attract, assimilate and retain sufficiently qualified personnel. The failure to retain and attract the necessary technical and managerial personnel could have a materially adverse effect on the Company’s business, prospects, financial condition and results of operations.

### Development of Brand Awareness

For certain market segments that Nuvilex plans to pursue, the development of its brand awareness is essential for it to reduce its marketing expenditures over time and realize greater benefits from marketing expenditures. If the Company’s brand-marketing efforts are unsuccessful, growth prospects, financial condition and results of operations would be materially adversely affected. Nuvilex’s brand awareness efforts have required, and will continue to require, incurrence of significant expenses.

### Intellectual Property Protection: Uncertainty of Protection of Proprietary Rights

Nuvilex currently relies on a combination of patents, trademarks, trade secret protection, non-disclosure agreements and licensing arrangements to establish and protect its proprietary rights. Despite efforts to safeguard and maintain Nuvilex’s proprietary rights, there can be no assurance that the Company will be successful in doing so or that its competitors will not independently develop products that are substantially equivalent or superior to Nuvilex’s products.

Nuvilex also relies on trade secrets and proprietary know-how, which the Company seeks to protect by confidentiality and non-disclosure agreements with its employees, consultants, and third parties. There can be no assurance that these agreements will not be breached, that the Company will have adequate remedies for any breach, or that certain of Nuvilex’s trade secrets and proprietary know-how will not otherwise become known or be discovered by competitors.

Litigation may become necessary to enforce Nuvilex’s intellectual property rights, to protect trade secrets, to determine the validity or scope of the proprietary rights of others, or to defend against claims of infringement or invalidity. Such litigation, whether successful or unsuccessful, could result in substantial costs and diversions of management resources, either of which could have a materially adverse effect on Nuvilex’s business, prospects, financial condition, or operating results.

### Availability and Coverage of Insurance

For certain risks, the Company does not maintain insurance coverage because of cost and/or availability. Because the Company retains some portion of its insurable risks, and in some cases self-insures completely, unforeseen or catastrophic losses in excess of insured limits could have a materially adverse effect on the Company’s financial condition and operating results.

### Federal, State, Local and Foreign Laws and Regulations

The Company’s past research, product development and manufacturing activities have involved the controlled use of hazardous materials, and the Company may incur significant costs as a result of the need to comply with numerous laws and regulations. The Company is subject to laws and regulations enforced by the FDA, the DEA, the CDHS, foreign health authorities and other regulatory statutes including the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Food, Drug and Cosmetic Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local and foreign laws and regulations governing the use, manufacture, storage, handling and disposal of the Company’s products, materials used to develop the Company’s products, and resulting waste products.

### Penny Stock Regulation

The Company’s securities may be subject to “penny stock rules” that impose additional sales requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 together with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser’s written consent to the transaction prior to the purchase. Additionally, for any transaction involving a penny stock, unless exempt, the “penny stock rules” require the delivery, prior to the transaction, of a disclosure schedule prescribed by the Securities and Exchange Commission relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Finally, monthly statements must be sent disclosing recent price information on the limited market in penny stocks. Consequently, the “penny stock rules” may restrict the ability of broker-dealers to sell the Company’s securities. The foregoing required penny stock restrictions will not apply to the Company’s common stock if such securities maintain a market price of $5.00 or greater. The market price of the Company’s common stock may not reach or remain at such a level.

Nuvilex anticipates it will expend significant financial and management resources in its efforts to comply with the internal control attestation provisions of Section 404 of the Sarbanes-Oxley Act of 2002 for the first quarter ending October 31, 2011.

Section 404 of the Sarbanes-Oxley Act of 2002, and the rules and regulations promulgated there under, require Nuvilex to have management attest to the adequacy of its internal controls in the Company’s annual report on Form 10-K for the year ending April 30, 2011. The Company’s internal controls did not meet such requirements on April 30, 2011 or October 31, 2011 and the Company is working to make changes to its internal controls in order for management to be able to make the required attestations by the end of the fiscal year ending April 30, 2012. Larger public companies currently required to comply with Section 404 have incurred significant monetary and other expenses from diversion of management time and attention, the acquisition of new computer software, the employment of additional personnel and training and third party internal controls consultants. In light of Nuvilex’s current capital position, the Company anticipates that it will be time-consuming, costly and difficult for it to develop and implement the internal controls necessary for management to make the required attestations. It is Nuvilex intention in any case, to do what is necessary regarding financial reporting and internal controls, through software, personnel, and third party consultants to succeed in implementing the necessary financial reporting and internal controls during year ended 2012.

Filed Dec 15, 2011.
Source: SEC EDGAR, the filing index for accession 0001262463-11-000325. Last ingested by Listed: Nov 14, 2026, 20:52 ET. No prices; not investment advice.
